COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Renal Atherosclerotic Revascularization Evaluation: RAVE Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00127738
Recruitment Status : Completed
First Posted : August 8, 2005
Last Update Posted : January 11, 2007
Information provided by:
Sunnybrook Health Sciences Centre

Brief Summary:
The RAVE study will compare renal revascularization to medical management for people with atherosclerotic renal vascular disease (ARVD) and the indication for revascularization.

Condition or disease Intervention/treatment Phase
Hypertension, Renovascular Procedure: Angiographic renal revascularization Not Applicable

Detailed Description:
It is uncertain whether patients with renal vascular disease will have renal or mortality benefits from re-establishing renal blood flow with renal revascularization procedures. Patients will be assessed for the standard nephrology research outcomes of progression to doubling of creatinine, need for dialysis, and death, as well as other cardiovascular outcomes. The investigators will also establish whether the use of a new inexpensive, simple and available ultrasound test, the renal resistance index (RRI), can identify patients with renal vascular disease who will not benefit from renal revascularization procedures.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : January 2005
Study Completion Date : December 2006

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Dialysis
  2. Death
  3. Doubling of creatinine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg despite at least 3 antihypertensive medications
  • Systolic blood pressure >140 mmHg and/or diastolic blood pressure > 90 mmHg on two antihypertensives with: a rise in creatinine > 20% after initiation of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB); the sudden onset of hypertension occurring after age 55; hypokalemia or the presence of an abdominal bruit; a history of flash pulmonary edema; or any three of: peripheral vascular disease, coronary artery disease, cerebrovascular disease, smoking, hyperlipidemia, diabetes or male gender.

Exclusion Criteria:

  • Serum creatinine > 220 umol/L or estimated glomerular filtration rate (GFR) by Cockroft-Gault equation < 20 ml/min
  • Patients who are unwilling or unable to give informed consent
  • Known contraindication to renal revascularization such as anaphylactic allergy to contrast dye
  • An abdominal aortic aneurysm requiring surgery
  • A single functioning kidney; a total occlusion of the renal artery or renal artery stenosis due to fibromuscular dysplasia.
  • Previous revascularization

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00127738

Layout table for location information
Canada, Ontario
Sunnybrook & Women's College Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
Sponsors and Collaborators
Sunnybrook Health Sciences Centre
Layout table for investigator information
Principal Investigator: Sheldon Tobe, MD Sunnybrook & Women's College Health Sciences Centre
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00127738    
Other Study ID Numbers: 216-2004
First Posted: August 8, 2005    Key Record Dates
Last Update Posted: January 11, 2007
Last Verified: February 2006
Keywords provided by Sunnybrook Health Sciences Centre:
Renal artery stenosis
Kidney disease
Renal vascular disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension, Renovascular
Vascular Diseases
Cardiovascular Diseases
Hypertension, Renal
Kidney Diseases
Urologic Diseases